HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment vs Tata India Pharma and Healthcare Fund Direct Plan Growth
NAV, returns and costs — not a recommendation.
 HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment |  Tata India Pharma and Healthcare Fund Direct Plan Growth | |
|---|---|---|
| NAV | ₹22.3 | ₹39.7747 |
| NAV date | 2026-08-18 | 2026-08-18 |
| 1 year | +25.46% | +9.62% |
| 3 year (p.a.) | +32.38% | +20.31% |
| 5 year (p.a.) | +32.38% | +15.52% |
| Expense ratio | 0.92% | 0.67% |
| Fund size | ₹2362.44 Cr | ₹1,455.16 Cr |
| Risk | — | — |
| Category | Sectoral Pharma and Healthcare | Sectoral Pharma and Healthcare |
Past performance does not guarantee future returns. Mutual fund investments are subject to market risks.